IDEXX Stock Gains Following the Acquisition of CoVet

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

Zacks Investment Research • Sep 17, 2026

IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.

Business Wire • Sep 17, 2026

IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.

Business Wire • Sep 16, 2026

IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock

The transaction involved 2,203 shares at $532.08 per share for a total value of ~$1.2 million. The director traded shares equal to 23% of the stake held before the filing.

The Motley Fool • Sep 10, 2026

Baron Partners Fund Q2 2026 Contributors And Detractors

Baron Partners Fund performed very well in the second quarter, gaining 16.61% (Institutional Shares). Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Top detractors include CoStar Group, Gartner, Guidewire Software, Morningstar and IDEXX Laboratories.

Seeking Alpha • Sep 10, 2026

Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Baron Focused Growth Fund Q2 2026 Portfolio Update

Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.

Seeking Alpha • Sep 3, 2026

Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 31, 2026

IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.

Business Wire • Aug 31, 2026